Tag: treatments

Milan, 29^th July 2025 – The Board of Directors of Recordati S.p.A. approved the interim financial statements as of June 30, 2025, pursuant to Art. 154-ter of Italian Legislative Decree 58/1998 and subsequent amendments, prepared in accordance with said Decree and the CONSOB Issuers Regulation. The statements were prepared in accordance with International Accounting Standard (IAS) 34 requirements for interim reporting, based on the assessment, measurement and recognition criteria set by the IFRSs. The interim financial statements on June 30, 2025 – as well as the Independent Auditors’ report on such statements - will be available within the legal deadline at the company’s offices and on the company’s website (www.recordati.com) and can also be viewed on the authorized storage system 1Info(www.1Info.it).

Innovative academic program contributes to a strong and sustainable talent pipeline for Canada’s national nuclear laboratories and Canadian nuclear sector

MUNICH, July 29, 2025 (GLOBE NEWSWIRE) -- Meliodays Medical and Celanese Corporation (NYSE: CE) have signed an agreement related to Meliodays’ pre-clinical development of MelioOne^®, the first hormone-free non-contraceptive intrauterine device (IUD) designed to deliver localized relief for menstrual pain. MelioOne^® combines the proven VitalDose^® Drug Delivery Platform from Celanese with Meliodays’ innovative IUD design and non-hormonal active pharmaceutical ingredient (API).

Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placement agent fees and other offering expenses. The Series A-3 Preferred Stock is initially convertible into an aggregate of 1,607,143 shares of common stock of the Company at a conversion price of $2.80 per share, subject to adjustment in accordance with the terms of the Series A-3 Preferred Stock Certificate of Designation.